Novo launches Saxenda in US, sees more launches in 2015

April 22, 2015 3:28 PM

8 0

COPENHAGEN (Reuters) - Novo Nordisk has launched its Saxenda obesity drug in the United States, it said on Wednesday, a long-awaited milestone that will provide a new revenue stream for the Danish drugmaker.

It will cost $1,068 per month, and the price paid by the individual patient will depend on his or her health insurance, the company said in an email to Reuters.

Read more

To category page